Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Prazer Therapeutics

Request full access

Our Mission is to provide novel therapeutic strategies

Seoul, South KoreaFounded 2019Biotech & Life Sciences

About Prazer Therapeutics

Prazer Therapeutics, a South Korean biotechnology firm founded in 2019, is focused on creating therapies for previously untreatable diseases. The company is headquartered in Seoul and its name is a combination of the words "protein" and "eraser," which reflects its mission to treat intractable conditions like neurodegenerative diseases and drug-resistant cancers by removing disease-related proteins. Prazer's core technology is its proprietary SPiDEM™ (Selective Protein Degradation Enabling Moiety) platform, a next-generation approach to Targeted Protein Degradation (TPD). This platform is engineered to overcome the limitations of earlier TPD methods, enabling the degradation of a wider range of targets, including aggregated and membrane proteins that were previously difficult to address. The company is developing orally available and blood-brain barrier-penetrating protein degraders.

The company's business model centers on the research and development of a pipeline of drug candidates, with the goal of entering into joint research and technology transfer agreements with global pharmaceutical companies. Prazer is actively developing new drugs for conditions such as Alzheimer's and Parkinson's diseases, as well as various cancers and inflammatory diseases. Its lead product in development is PRX302, a Tau-targeting agent. The company's work has gained significant recognition, including winning the Seoul BMS Innovation Challenge in 2022 and securing second place in the 2023 Boehringer Ingelheim Innovation Prize in Japan. Prazer has also established strategic collaborations with partners like Yuhan Corporation and Daewon Pharmaceutical.

Prazer Therapeutics has successfully secured substantial funding to advance its research and development efforts. In March 2025, the company closed a ₩29 billion (approximately $20 million) Series B funding round. This round was notably led by Johnson & Johnson Innovation – JJDC, Inc., the venture capital arm of Johnson & Johnson. Other investors included Premier Partners, K2 Investment, Mirae Asset Capital, Quad Asset Management, and STIC Ventures, with follow-on investments from earlier Series A backers like Company K Partners, Kiwoom Investment, and Smilegate Investment. This capital is earmarked for accelerating new drug development and supporting global commercialization. The company is also a member of Johnson & Johnson's JLABS, a global accelerator platform.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2019
Headquarters
Seoul, South Korea
Employees
27
Open positions
None listed
Dealroom signal
88.7/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Jul 2026 $42M $168M Premier Partners · Johnson & Johnson Innovation · SmileGate Investment · Underground Ventures ↗
SERIES BOther financing Apr 2025 $24M $97M SmileGate Investment · Company K Partners · Kiwoom Investment · K2 Investment Partners ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Prazer Therapeutics website traffic

Latest recorded traffic for Prazer Therapeutics is 2.3K monthly website visits, down 69.7% over the last three months. Prazer Therapeutics's team grew 42.1% over the past year.

Latest monthly visits2.3K 3-month web change-69.7% 1-year team growth+42.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Prazer Therapeutics in the Seoul ecosystem

Live from Dealroom

The Prazer Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

18 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

  • Johnson & Johnson Innovation
  • SmileGate Investment
  • Company K Partners
  • Kiwoom Investment
  • K2 Investment Partners
  • STIC Ventures
  • Quad Asset Management
  • Premier Partners
  • Mirae Asset Capital

Series B and later8 investors entered at this stage

  • Underground Ventures
  • K2 Investment
  • Hana Securities
  • Chant Venture Fund (I.L.P)
  • Shinhan Asset Management
  • GO INVEST LLC
  • Mirae Asset Securities
  • Woori Venture Partners

Other known investors1 additional known investor

  • Kyung Hee University
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇰🇷 South Korea85.7%
🇺🇸 United States14.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Prazer Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Prazer Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.